[PDF] wiley.comFull View

Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5

RF Kushner, S Calanna, M Davies, D Dicker… - …, 2020 - Wiley Online Library
Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle
interventions. The Semaglutide Treatment Effect in People with obesity (STEP) program
aims to investigate the effect of semaglutide versus placebo on weight loss, safety, and
tolerability in adults with obesity or overweight. Methods Across five phase 3 trials
(NCT03548935, WM; NCT03552757, WM in type 2 diabetes; NCT03611582, WM with …
被引用次数：270 相关文章 所有 14 个版本

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushnerq, S Calanna, M Davies, D Dicker… - …, 2020 - search.proquest.com
Objective: The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle
interventions. The Semaglutide Treatment Effect in People with obesity (STEP) program
aims to investigate the effect of semaglutide versus placebo on weight loss, safety, and
tolerability in adults with obesity or overweight. Methods: Across five phase 3 trials
(NCT03548935, WM; NCT03552757, WM in type 2 diabetes; NCT03611582, WM with …
被引用次数：3 相关文章
以上显示的是最相近的搜索结果。 查看全部搜索结果